Novavax Company Profile (NASDAQ:NVAX)

About Novavax

Novavax logoNovavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: NVAX
  • CUSIP: 67000210
Key Metrics:
  • Previous Close: $1.51
  • 50 Day Moving Average: $1.34
  • 200 Day Moving Average: $3.04
  • 52-Week Range: $271,193,000.00 - $1.16
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.29
  • P/E Growth: 0.00
  • Market Cap: $409.50M
  • Outstanding Shares: 271,193,000
  • Beta: 1.72
Profitability:
  • Net Margins: -1,908.41%
  • Return on Equity: -189.14%
  • Return on Assets: -61.47%
Debt:
  • Debt-to-Equity Ratio: 6.35%
  • Current Ratio: 4.68%
  • Quick Ratio: 4.68%
Additional Links:
Companies Related to Novavax:

Analyst Ratings

Consensus Ratings for Novavax (NASDAQ:NVAX) (?)
Ratings Breakdown: 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $6.41 (324.36% upside)

Analysts' Ratings History for Novavax (NASDAQ:NVAX)
Show:
DateFirmActionRatingPrice TargetDetails
1/20/2017Cantor FitzgeraldReiterated RatingHold$2.00View Rating Details
1/18/2017FBR & CoReiterated RatingOutperform$12.00View Rating Details
11/11/2016WedbushReiterated RatingNeutral$2.00 -> $1.50View Rating Details
11/11/2016Chardan CapitalReiterated RatingNeutral$1.50View Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHoldView Rating Details
9/16/2016S&P Equity ResearchLower Price Target$1.44 -> $1.17View Rating Details
9/16/2016Citigroup Inc.DowngradeBuy -> Neutral$12.00 -> $1.50View Rating Details
9/16/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$14.00 -> $1.00View Rating Details
9/16/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralView Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00View Rating Details
4/7/2015Janney Montgomery ScottReiterated Rating$12.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Novavax (NASDAQ:NVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
11/9/2016Q316($0.26)($0.24)$4.02 million$3.20 millionViewListenView Earnings Details
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novavax (NASDAQ:NVAX)
Current Year EPS Consensus Estimate: $-1.05 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.27)($0.13)($0.22)
Q2 20163($0.28)($0.13)($0.19)
Q3 20162($0.27)($0.24)($0.26)
Q4 20162($0.24)($0.23)($0.24)
Q1 20172($0.17)($0.15)($0.16)
Q2 20172($0.16)($0.16)($0.16)
Q3 20172($0.17)($0.17)($0.17)
Q4 20172($0.17)($0.14)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Novavax (NASDAQ:NVAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Novavax (NASDAQ:NVAX)
Insider Ownership Percentage: 3.50%
Institutional Ownership Percentage: 60.36%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/31/2017Barclay A. PhillipsCFOBuy1,633$1.12$1,828.96View SEC Filing  
1/31/2017John A. Herrmann IIISVPBuy4,960$1.12$5,555.20View SEC Filing  
12/7/2016Gregory M GlennInsiderBuy1,000$1.45$1,450.00View SEC Filing  
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.00View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.00View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.80View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.36View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.00View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.00View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.00View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.72View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.72View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.64View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Novavax (NASDAQ:NVAX)
DateHeadline
News IconNovavax, Inc. (NASDAQ:NVAX) Volume Spiking Mid-session - Winfield Review (NASDAQ:NVAX)
winfieldreview.com - February 18 at 11:52 AM
News IconNovavax, Inc. (NVAX): Essential Chart Information - NY Stock News (NASDAQ:NVAX)
nystocknews.com - February 18 at 11:52 AM
News IconA Technical Look At 2 Stocks: Novavax, Inc. (NVAX), GNC Holdings, Inc. (GNC) - Post Analyst (NASDAQ:NVAX)
postanalyst.com - February 17 at 8:22 AM
News IconNew Nintendo Switch Trailers Focuses More On Multiplayer Feature (NASDAQ:NVAX)
eleganthomesinla.com - February 16 at 6:29 PM
fool.com logoBetter Buy: Novavax, Inc. vs. Inovio Pharmaceuticals (NASDAQ:NVAX)
www.fool.com - February 16 at 11:16 AM
News IconStock Price of Peregrine Pharmaceuticals Inc. (PPHM) Increases 13.79% (NASDAQ:NVAX)
ekosvoice.com - February 14 at 10:06 PM
capitalcube.com logoNovavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : February 14, 2017 (NASDAQ:NVAX)
www.capitalcube.com - February 14 at 10:06 PM
insidermonkey.com logoCluster of Insider Buying at Clinical-Stage Vaccine Company, Massive Insider Selling at Analog Chip Giant, Plus Other Insider Trading (NASDAQ:NVAX)
www.insidermonkey.com - February 12 at 12:01 AM
News IconAn Inside Look at Trading Hot Stocks: Novavax, Inc. (NVAX), Diplomat Pharmacy, Inc. (DPLO) - Post Analyst (NASDAQ:NVAX)
postanalyst.com - February 11 at 1:06 AM
News Icon(NASDAQ:PTEN), Novavax, Inc. (NASDAQ:NVAX) (NASDAQ:NVAX)
latribunadecanarias.com - February 9 at 7:59 PM
News IconStock Under Focus: Novavax, Inc. (NASDAQ:NVAX) - The Oracle Examiner (NASDAQ:NVAX)
oracleexaminer.com - February 7 at 4:28 PM
istreetwire.com logoTrader's Round Up: EnteroMedics Inc. (ETRM), Novavax, Inc. (NVAX), Ascena Retail Group, Inc. (ASNA) - iStreetWire (NASDAQ:NVAX)
istreetwire.com - February 7 at 4:28 PM
News IconSpringsteen plays 'Don't Hang Up' in Melbourne as a message to Trump (NASDAQ:NVAX)
mundoaguaysaneamiento.net - February 2 at 7:50 PM
News IconNovavax, Inc. (NASDAQ:NVAX) Commences Phase II Safety and Immunogenicity Study Of The RSV F Vaccine (NASDAQ:NVAX)
www.financialstrend.com - February 1 at 8:02 PM
News IconWhat are Brokerage Firms Saying About Novavax, Inc. (NASDAQ:NVAX)? - Aiken Advocate (NASDAQ:NVAX)
aikenadvocate.com - January 31 at 12:40 AM
News IconAre Insiders Bumping Up Their Positions in Novavax, Inc. (NASDAQ:NVAX) - Wall Street Beacon (NASDAQ:NVAX)
wsbeacon.com - January 31 at 12:40 AM
News IconHow Does Novavax, Inc. (NVAX) Stack Up Right Now? - StockNewsJournal (NASDAQ:NVAX)
stocknewsjournal.com - January 31 at 12:40 AM
News IconDrilling Down Into the Charts for Novavax, Inc. (NVAX) - The USA Commerce (NASDAQ:NVAX)
theusacommerce.com - January 29 at 12:11 AM
capitalcube.com logoNovavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : January 27, 2017 (NASDAQ:NVAX)
www.capitalcube.com - January 28 at 5:17 AM
fool.com logoCan Novavax Stay Ahead of the Competition? (NASDAQ:NVAX)
www.fool.com - January 27 at 5:02 PM
News IconNovavax, Inc. (NASDAQ:NVAX) Daily Sentiment Score At 0.31 - Stock Observer (NASDAQ:NVAX)
www.thestockobserver.com - January 26 at 11:43 PM
News IconJust the Facts on Novavax, Inc. (NVAX) - StockNewsJournal (NASDAQ:NVAX)
stocknewsjournal.com - January 26 at 11:43 PM
News IconHost Hotels & Resorts, Inc. (NYSE:HST), Novavax, Inc. (NASDAQ:NVAX) (NASDAQ:NVAX)
twnewsjp.com - January 25 at 10:06 PM
News IconNovavax, Inc. (NVAX) Stock Price Decreases -5.59% - Highland Mirror (NASDAQ:NVAX)
www.highlandmirror.com - January 25 at 5:45 AM
istreetwire.com logoStocks To Track: Host Hotels & Resorts, Inc. (HST), Novavax, Inc. (NVAX), Alcoa Corporation (AA) - iStreetWire (NASDAQ:NVAX)
istreetwire.com - January 24 at 8:58 AM
News IconCantor Fitzgerald Releases a Hold Rating on Novavax (NASDAQ:NVAX)
myhealthbowl.com - January 22 at 1:32 AM
News IconNovavax Inc NVAX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:NVAX)
www.bioportfolio.com - January 21 at 6:42 PM
smarteranalyst.com logoFBR Optimistic on Novavax, Inc. (NVAX) Following Management Meeting (NASDAQ:NVAX)
www.smarteranalyst.com - January 20 at 7:43 PM
streetinsider.com logoNovavax (NVAX) Initiates Phase 2 Trial of RSV F Vaccine in Older Adults (NASDAQ:NVAX)
www.streetinsider.com - January 19 at 11:27 PM
finanznachrichten.de logoNovavax, Inc.: Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults (NASDAQ:NVAX)
www.finanznachrichten.de - January 19 at 11:27 PM
smarteranalyst.com logoCompany Update (NASDAQ:NVAX): Novavax, Inc. Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults (NASDAQ:NVAX)
www.smarteranalyst.com - January 19 at 11:27 PM
finance.yahoo.com logo4:06 pm Novavax announces the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate in older adults (NASDAQ:NVAX)
finance.yahoo.com - January 19 at 11:27 PM
finance.yahoo.com logoNovavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults (NASDAQ:NVAX)
finance.yahoo.com - January 19 at 11:27 PM
bizjournals.com logoNovavax starts new clinical trial in bid to prove failed RSV vaccine (NASDAQ:NVAX)
www.bizjournals.com - January 19 at 11:27 PM
News IconNovavax, Inc. (NASDAQ:NVAX) showed P/E ratio of 0 - The Newburgh Press (NASDAQ:NVAX)
newburghpress.com - January 19 at 12:33 AM
fool.com logoBetter Buy: Novavax, Inc. vs. Roche (NASDAQ:NVAX)
www.fool.com - January 16 at 10:34 AM
News IconNovavax, Inc. (NVAX) stock slips, “Hold” rating reaffirmed by Cantor ... - The Ledger Gazette (NASDAQ:NVAX)
ledgergazette.com - January 16 at 7:57 AM
News IconBrokers Watch List: Novavax, Inc. (NVAX), Ocwen Financial Corp. (OCN) - The Newburgh Press (NASDAQ:NVAX)
newburghpress.com - January 15 at 12:01 AM
News IconD.C.-area biotech stocks, led by United Therapeutics Corp. (NASDAQ: UTHR) and Novavax Inc. (NASDAQ: NVAX) fall on Donald Trump's tough talk (NASDAQ:NVAX)
www.yahoo.com - January 13 at 11:35 PM
seekingalpha.com logoNovavax (NVAX) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:NVAX)
seekingalpha.com - January 13 at 11:35 PM
News IconFinancial Watchlist of Novavax, Inc. (NASDAQ:NVAX) - The Newburgh Press (NASDAQ:NVAX)
newburghpress.com - January 13 at 5:36 AM
News IconInsider Activity for Investors: United States Steel Corp. (NYSE:X) (NASDAQ:NVAX)
baddgoddess.com - January 13 at 12:34 AM
feeds.benzinga.com logoFor A Tarnished Novavax, An Effective Zika Vaccine Could Be The Only Cure (NASDAQ:NVAX)
feeds.benzinga.com - January 12 at 2:01 PM
istreetwire.com logoTraders Recap: Novavax, Inc. (NVAX), Medtronic plc (MDT ... - iStreetWire (NASDAQ:NVAX)
istreetwire.com - January 11 at 7:32 PM
News IconNovavax, Inc. (NASDAQ:NVAX) Quarterly EPS Set At $-0.165 - Stock Observer (NASDAQ:NVAX)
www.thestockobserver.com - January 11 at 12:54 AM
istreetwire.com logoStocks Under Review: Marathon Petroleum Corporation (MPC ... - iStreetWire (NASDAQ:NVAX)
istreetwire.com - January 11 at 12:54 AM
capitalcube.com logoNovavax, Inc. – Value Analysis (NASDAQ:NVAX) : January 10, 2017 (NASDAQ:NVAX)
www.capitalcube.com - January 10 at 7:49 PM
capitalcube.com logoNovavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : January 9, 2017 (NASDAQ:NVAX)
www.capitalcube.com - January 9 at 7:39 PM
fool.com logoNovavax, Inc. Stock Sank 83% in 2016 -- Could 2017 Be Even Worse? (NASDAQ:NVAX)
www.fool.com - January 6 at 10:24 AM
News IconDaily Sentiment Score Of Novavax, Inc. (NASDAQ:NVAX) At -0.024 - Stock Observer (NASDAQ:NVAX)
www.thestockobserver.com - January 6 at 3:37 AM

Social

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Where is Novavax's stock going? Where will Novavax's stock price be in 2017?

9 brokers have issued 1 year price objectives for Novavax's shares. Their forecasts range from $1.00 to $25.00. On average, they anticipate Novavax's stock price to reach $6.41 in the next twelve months.

When will Novavax announce their earnings?

Novavax is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:

  • According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (1/21/2017)

  • Cantor Fitzgerald analysts commented, "RSV maternal vaccination likely primary value driver in 2017. We believe investors will be keenly focused on the RSV vaccine when used in the context of maternal vaccination, particularly given the failure of the elderly subject RSV pivotal trial late last year. Clinical data suggest that the vaccine is immunogenic in pregnant women and that anti-RS F protein antibodies are efficiently transferred across the placenta to the fetus." (1/12/2017)

  • Piper Jaffray Companies analysts commented, "So, Now What?" (9/16/2016)

Who owns Novavax stock?

Novavax's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (7.82%), State Street Corp (7.36%), Franklin Resources Inc. (2.02%), Eventide Asset Management LLC (0.53%), Alden Global Capital LLC (0.24%) and Royce & Associates LP (0.20%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rajiv I Modi and Stanley C Erck.

Who sold Novavax stock? Who is selling Novavax stock?

Novavax's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Eventide Asset Management LLC, Oxford Asset Management, Royce & Associates LP, Commerzbank Aktiengesellschaft FI, Brown Advisory Inc. and Frontier Capital Management Co. LLC. Company insiders that have sold Novavax stock in the last year include Gary C Evans and Stanley C Erck.

Who bought Novavax stock? Who is buying Novavax stock?

Novavax's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Alden Global Capital LLC, Renaissance Technologies LLC, Perceptive Advisors LLC and Metropolitan Life Insurance Co. NY. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck.

How do I buy Novavax stock?

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Novavax stock cost?

One share of Novavax stock can currently be purchased for approximately $1.51.

Novavax (NASDAQ:NVAX) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Earnings History Chart

Earnings by Quarter for Novavax (NASDAQ:NVAX)

Dividend History Chart

Dividend Payments by Quarter for Novavax (NASDAQ:NVAX)

Last Updated on 2/20/2017 by MarketBeat.com Staff